Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-27T22:18:13.540Z Has data issue: false hasContentIssue false

Debate 6B - In Patients with BRCA-negative and HRD-negative Epithelial Ovarian Cancer, Should Molecular Profiling be Routinely Done to Guide Adjuvant Therapy?

No

from Section III - Ovarian Cancer

Published online by Cambridge University Press:  20 July 2023

By
Raanan Alter  and
Ernst Lengyel
Edited by
Dennis S. Chi ,
Nisha Lakhi  and
Nicoletta Colombo
Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

In the era of targeted medicine, the use of poly (ADP-ribose) polymerase (PARP) inhibitors in homologous recombination deficient (HRD) tumors has represented the first clinically actionable mutation in gynecologic malignancies. The dramatic results seen across multiple clinical trials completely changed the landscape of epithelial ovarian cancer (EOC) treatments in both primary and recurrent settings. For many, it has spawned hope that additional biomarkers would soon be discovered that could find similarly spectacular results in different patient populations. However, molecular profiling’s efficacy in selecting targeted therapies and its economic practicality are difficult to justify.

Type
Chapter
Information
50 Big Debates in Gynecologic Oncology , pp. 32 - 34
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Flaherty, KT, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol 2020;38(33):3883–3894.CrossRefGoogle Scholar
Lee, YJ, et al. Integrating a next generation sequencing panel into clinical practice in ovarian cancer. Yonsei Med J 2019;60(10):914–923.CrossRefGoogle ScholarPubMed
Kuderer, NM, et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol 2017;3(7):996–998.CrossRefGoogle ScholarPubMed
Haunschild, CE, et al. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol 2020;160(1):333–345.CrossRefGoogle ScholarPubMed
Wallbillich, JJ, et al. A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy. Gynecol Oncol 2016;142(1):144–149.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×